‘Expanding access to justice': First five Purdue Global Law School students admitted to Indiana bar
The first five graduates from Purdue University Global Law School took their new attorney's oath Tuesday morning, marking a milestone for both the school and Indiana's legal system.
At the ceremony held at the Indiana Roof Ballroom, the Indiana Supreme Court admitted 68 new attorneys, including the Purdue Global Law graduates.
The ceremony was attended by all five justices of the Indiana Supreme Court, as well as judges from the U.S. District Courts for the Northern and Southern Districts, the Indiana Court of Appeals, and the Indiana Tax Court.
The ceremony follows a July 2024 amendment to Indiana's Rules of Admission and Discipline Rule 13 that allowed graduates of non-American Bar Association accredited, Indiana-based online law schools to sit for the Indiana bar exam.
It was meant to address the state's justice gap in rural or other underserved areas.
This amendment made Purdue Global Law graduates eligible to sit for the bar exam upon graduation. At the time, California was the only other state that allowed such eligibility.
Indiana currently has a lawyer shortage. Indiana Court of Appeals Chief Judge Robert Altice told the graduates Tuesday that out of 6.8 million Hoosiers, only 19,055 are lawyers.
'You are joining a very special group today,' Altice said. 'As less than 1% of our total population, I encourage you to think about a small specialized group you are.'
All five eligible Purdue Global Law graduates passed the February Indiana Bar Exam on their first attempt. According to Indiana Bar exam result data, Indiana's overall pass rate for first time takers is 63%. The graduates are:
Joud Elias
Lindley Jarrett
Jeff Kraft
Daniel Stahoviak
Abby Strehle
Strehle is a nurse practitioner, mother and now dual-licensed attorney in both Indiana and California. She attended Purdue for her undergraduate degree 26 years ago and received a Bachelor of Science in Nursing from the University of Indianapolis. Following that she completed her Master of Science and became a licensed Nurse Practitioner.
Strehle said she always had an interest in law so she returned to Purdue Global Law's fully online program. She completed her law degree in August 2023 while continuing to work in healthcare and raising her family in Bargersville, Indiana.
'I wasn't willing to give up my nights or time with my kids for a traditional law school,' she said.
Strehle, the owner and founder of Encompass Legal Services, now practices disability law in all 50 states. She said she wanted to take her experience in the medical field into the legal one.
'I've seen the other side,' she said. 'I know what people are going through when making either end-life decisions or something that disrupts their entire life.'
She said that her online law school experience was far from easy but she was able to make connections and even some close friends online. She said the courses are set up in similar formats including course work, weekly zoom meetings and breakout sessions.
Strehel said the Indiana Supreme Court amendment that created the path for Purdue Global Law graduates to become eligible for the bar exam means everything to her.
'When I applied to Purdue Global, I only hoped that being licensed in Indiana would be a thing,' she said. 'The fact that I can be licensed in Indiana allows me to really do what I want to do and the reason why I did what I wanted.'
Dean of Purdue Global Law School, Martin Pritikin called the moment 'a turning point' for access to justice. Pritikin was a professor and administrator of a traditional law school for 12 years before he became interested in online education.
Purdue Global Law — previously called Concord Law School — was founded in 1998 and was one of the nation's first fully online law schools. Pritikin said the school operates at one-third of the cost of traditional programs and is designed for nontraditional students – working professionals or others who need flexibility.
'Our typical student is not someone who went straight from high school to college to law school,' he said. 'Even though they may be new lawyers they are not new to the workforce.'
Pritikin said the curriculum at Purdue Global is as 'rigorous' as anything someone would get at a traditional law school. He said that people think the school is easy because it's online, but that's not the case.
Pritikin said the Indiana Supreme Court 'took a chance' on Purdue Global, and hopes the school is a big part of solving the access to justice crisis. He noted more than half of the students enrolling are not from Indianapolis — they are from rural, small and underserved areas.
The school currently has 78 Indiana-based students enrolled — about 10% of total enrollment.
'It's the best way to get more lawyers in underserved areas and to make it easier for people in those areas to stay where they are to attend law school.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
29 minutes ago
- Bloomberg
KKR-Backed Firm Buys Gulf Capital's Mideast Fertility Business
A firm backed by KKR & Co. has bought Gulf Capital PJSC's stake in its Middle Eastern fertility business, underscoring the rising demand for specialty medical services in the region. The Abu Dhabi-based group had been working with Moelis & Co. on the sale of ART Fertility Clinics' Middle East operations to IVI RMA Global, the world's largest provider of infertility treatments that was acquired by buyout giant KKR three years ago.
Yahoo
an hour ago
- Yahoo
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
Revenue Decline of 3.7% at Constant Exchange Rate (CER); 8.4% Decline at Actual Exchange Rates (AER) as VYVANSE® Generic Erosion Impacts Revenue in Line With Company Expectations Core Operating Profit Decline of 11.9% at CER, Primarily Reflecting Generic Erosion Reported Operating Profit Increase of 11.0% at AER, Reflecting Lower YoY Impairment and Restructuring Expenses Positive Results from Two Pivotal Phase 3 Studies of Oveporexton in Narcolepsy Type 1 Reinforce Continued Momentum in Late-Stage Pipeline No Change to Full-Year Outlook Announced in May OSAKA, Japan, July 30, 2025--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory and underscoring its commitment to delivering sustainable value through innovation. Most notably, both Phase 3 studies of oveporexton successfully met all primary and secondary endpoints, demonstrating statistically significant improvements across doses. These results reinforce the potential of oveporexton to transform the standard of care in narcolepsy type 1. In addition, Takeda received U.S. FDA approval for GAMMAGARD® LIQUID ERC and European Commission (EC) approval for ADCETRIS® in new indications and presented promising clinical data for rusfertide at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session. These developments underscore the strength of Takeda's late-stage pipeline and its potential to drive future growth. Takeda chief financial officer, Milano Furuta, commented:"The impact of VYVANSE generic erosion on Takeda's FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May. "Our late-stage pipeline continues to advance with the announcement in July of positive results from two pivotal Phase 3 studies for oveporexton in narcolepsy type 1, with both studies meeting all primary and secondary endpoints. These results represent a significant scientific milestone, and we are very excited about the potential for our late-stage pipeline to deliver value to the patients we serve and to position Takeda for sustainable growth." FINANCIAL HIGHLIGHTS for FY2025 Q1 Ended June 30, 2025 (Billion yen, except percentages and per share amounts) FY2025 Q1 FY2024 Q1 vs. PRIOR YEAR (Actual % change) Revenue 1,106.7 1,208.0 -8.4% Operating Profit 184.6 166.3 +11.0% Net Profit 124.2 95.2 +30.4% EPS (Yen) 79 61 +30.8% Operating Cash Flow 215.4 170.3 +26.5% Adjusted Free Cash Flow (Non-IFRS) 190.1 23.7 +703.6% Core (Non-IFRS) (Billion yen, except percentages and per share amounts) FY2025 Q1 FY2024 Q1 vs. PRIOR YEAR (Actual % change) vs. PRIOR YEAR (CER % change) Revenue 1,106.7 1,208.0 -8.4% -3.7% Operating Profit 321.8 382.3 -15.8 % -11.9% Margin 29.1% 31.6% -2.6 pp ― Net Profit 237.0 276.8 -14.4% -10.3% EPS (Yen) 151 176 -14.1% -10.0% FY2025 Outlook (unchanged from May 2025) (Billion yen, except percentages and per share amounts) FY2025 FORECAST FY2025 MANAGEMENT GUIDANCE Core Change at CER (Non-IFRS) Revenue 4,530.0 --- Core Revenue (Non-IFRS) 4,530.0 Broadly flat Operating Profit 475.0 --- Core Operating Profit (Non-IFRS) 1,140.0 Broadly flat Net Profit 228.0 --- EPS (Yen) 145 --- Core EPS (Yen) (Non-IFRS) 485 Broadly flat Adjusted Free Cash Flow (Non-IFRS) 750.0-850.0 --- Annual Dividend per Share (Yen) 200 --- Additional Information About Takeda's FY2025 Q1 ResultsFor more details about Takeda's FY2025 Q1 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda's FY2025 Q1 investor presentation (available at About TakedaTakeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Important NoticeFor the purposes of this notice, "press release" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners. Forward-Looking StatementsThis press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: at does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Financial information and Non-IFRS MeasuresTakeda's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"). This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate ("CER") change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda's management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda's non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as "reported" measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2025 Q1 investor presentation (available at Peak Sales and PTRS EstimatesReferences in this press release to peak revenue potential ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue potential ranges represent Takeda's assessments of various possible future commercial scenarios that may or may not occur. References in this press release to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda's Portfolio Review Committee for use in internal planning. Medical informationThis press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Please refer to slide 6 of Takeda's FY2025 Q1 investor presentation (available at for the definition of Growth & Launch Products. View source version on Contacts Investor Relations Christopher O' +81 (0) 90-6481-3412 Media Relations Brendan +81 (0) 80-2705-8259(Outside Japan business hours)Media_Relations@
Yahoo
an hour ago
- Yahoo
Hedge fund tycoon Hosking says rival Telegraph bid "ready to go"
The hedge fund founder enlisted to back a bid for The Daily Telegraph says the offer is "ready to go" if a takeover of the broadsheet title involving sovereign Gulf money runs into further regulatory problems. Sky News has learnt that Jeremy Hosking, the prominent City figure who co-founded Marathon Asset Management, is pledging to inject £100m of his own money into the newspaper group if the self-styled 'British bid' of which he is part is successful. Mr Hosking, who now runs Hosking Partners, has been working with Dovid Efune, the owner of the New York Sun, in an effort to gain control of the Telegraph for several months. Money latest: They have been thwarted, though, by an agreement reached with RedBird Capital Partners, the US-based investment firm, to buy the titles for £500m following a two-year battle which has plunged the Telegraph into a protracted state of limbo. RedBird's bid includes tens of millions of pounds of funding from IMI, a state-backed Abu Dhabi vehicle, which cleared a key hurdle last week when the House of Lords voted against a 'fatal motion' which would have blocked the sovereign investment. The outcome of the vote was not without fierce debate, with 155 peers supporting the ban. IMI is controlled by Sheikh Mansour bin Zayed Al Nahyan, the vice-president of the United Arab Emirates and ultimate owner of Manchester City Football Club. Speaking through Mr Efune, Mr Hosking said in a statement on Wednesday morning: "We have been following the latest developments closely and with the best outcome for all Telegraph stakeholders front of mind. "We understand from the Lords debate last week that there is now a legal requirement for the government to formally investigate all the foreign government ties that may result in influence over the current preferred buyer. "Should the buyer be deemed unsuitable, our "British Bid" is ready to go. "We believe our current capitalization is more than adequate to replace the controlling shareholder's portion of the deal. "My own personal commitment is £100m in equity capital." Further details of the financing lined up by Mr Efune's consortium remain unclear, including the level of debt attached to his prospective offer. The RedBird-led acquisition of the Telegraph remains subject to investigations by both Ofcom and the Competition and Markets Authority, which are likely to delay completion of the deal into next year. Sky News previously revealed that Sir Leonard Blavatnik, owner of the DAZN sports streaming platform, and Daily Mail proprietor Lord Rothermere were preparing to buy minority stakes as part of the RedBird transaction. Gerry Cardinale, the RedBird executive, who has spearheaded the latest iteration of its acquisition, has described the firm as "the right owner at the right time". RedBird said in May that it was "in discussions with select UK-based minority investors with print media expertise and strong commitment to upholding the editorial values of the Telegraph". The Telegraph titles' parent company was forced into insolvency proceedings in 2023 by Lloyds Banking Group, which ran out of patience with the Barclay family, their long-standing owner. RedBird IMI, a joint venture between the two firms, paid £600m several months later to acquire a call option that was intended to convert into ownership of the Telegraph newspapers and The Spectator magazine. That objective was thwarted by a change in media ownership laws - which banned any form of foreign state ownership. Some peers argued last week that a 15% threshold was too high and that the legislation to permit it was dangerously ambiguous because it could allow for more than one state investor to aggregate their holdings in British newspapers. A further statutory instrument will need to be approved in order to address this issue. The Spectator, which had also been part of the same group, was sold last year for £100m to Sir Paul Marshall, the hedge fund billionaire, who has installed Lord Gove, the former cabinet minister, as its editor.
